How did Adamis Pharmaceuticals Corporation (ADMP) stock recovered from its early loss on Monday?

Related Topics

Facebook
Twitter
LinkedIn
WhatsApp

Adamis Pharmaceuticals Corporation (ADMP) shares surged 6.71% in after-hours on Monday, August 16, 2021, and closed the daily trading at $0.96. In the regular trading session of Monday, ADMP’s stock lost 7.34%. ADMP shares have fallen 3.35% over the last 12 months, and they have moved down 10.85% in the past week. Over the past three months, the stock has gained 20.91%, while over the past six months, it has declined 41.52%.

ADMP sold its US Compounding Business

On August 04, 2021, Adamis Pharmaceuticals Corporation (ADMP) entered into a definitive agreement to sell a significant portion of the assets of its subsidiary, US Compounding Inc. (USC), related to USC’s human compounding pharmaceutical business and customers, in exchange for total gross consideration estimated to be up to $15 million before transaction fees and expenses.

ADMP 2021 AGM results

On July 19, 2021, Adamis Pharmaceuticals Corporation (ADMP) announced that based on the Inspector of Election’s certified results from the Company’s 2021 Annual Meeting of Stockholders, each of the Company’s nominees, Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo, PhD, David J. Marguglio and Richard C. Williams, have been re-elected to the Board of Directors. The stockholders approved all other proposals considered at the Annual Meeting. The Board thanks the Adamis stockholders for their engagement and support.

ADMP provided an update about Tempol

On June 11, 2021, Adamis Pharmaceuticals Corporation (ADMP) announced that clinical trial start-up activities are underway for examining the effects of Tempol, which is the Company’s experimental drug, in the treatment of COVID-19. Adamis is carrying out these activities with a large clinical research organization (CRO).

Update about ZIMHI

On June 09, 2021, Adamis Pharmaceuticals Corporation (ADMP) announced that the U.S. Food and Drug Administration has accepted for review the Company’s resubmitted New Drug Application (NDA) for ZIMHI™, which is its higher naloxone injection product candidate for the treatment of opioid overdose. The FDA also provided a target action date under the Prescription Drug User Fee Act (PDUFA date) of November 12, 2021.

ADMP Recent business updates

On June 01, 2021, Adamis Pharmaceuticals Corporation provided an important business update.

SYMJEPI® (epinephrine) Injection update

The company said that both SYMJEPI products are now available at a discounted price of $99.99 per two-pack through the Walgreens Prescription Savings Club.

The company’s new commercial partner, US WorldMeds, is making exceptional gains in the epinephrine market.

After transitioning the product from Sandoz SYMJEPI unit sales have increased approximately 90% for the five months from December 2020 through April 2021 compared to the same five-month period of the prior year.

Conclusion

Well, as of this writing, we have no reason to justify its poor start on Monday and also there is no recent news that could be linked with its recovery in the after-hours on Monday.

Leave a Comment

Your email address will not be published.

Latest Posts